Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 71NIH 25INDUSTRY 17NETWORK 12UNKNOWN 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pathologic Complete Response 1Breast Neoplasms 1

Interventions

Radiotherapy 10Cisplatin 9Carboplatin 7Capecitabine 6Neoadjuvant Therapy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Paclitaxel 4Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Surgical Procedures, Operative 3Oxaliplatin 3Hydralazine 3Etoposide 3Drug Therapy 3pertuzumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2endostar protein 2Valproic Acid 2Tranexamic Acid 2Temozolomide 2TP protocol 2Saline Solution 2Radiotherapy, Adjuvant 2Radiation 2Proton Pump Inhibitors 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × Epirubicin × Clear all
NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡